Alan Lichtenstein
Impact in
- Hematology top 0.1%
- Multiple Myeloma Research and Treatments
- Iron Metabolism and Disorders
- Microbiology top 0.2%
- Antimicrobial Peptides and Activities
Papers in
-
- PI3K/AKT/mTOR signaling in cancer 31
- Protein Kinase Regulation and GTPase Signaling 10
- Hematology 60
- Multiple Myeloma Research and Treatments 58
- Co-authors
- Tomas Ganz (7 shared papers)Joseph Gera (39 shared papers)Yijiang Shi (33 shared papers)Robert I. Lehrer (3 shared papers)Yiping Tu (10 shared papers)Elizabeta Nemeth (3 shared papers)Gary J. Schiller (5 shared papers)Mary Territo (1 shared paper)
- Journals
- Blood (30 papers)Cellular Immunology (10 papers)Journal of Biological Chemistry (10 papers)Molecular Cancer Therapeutics (8 papers)Oncogene (6 papers)
- Partner nations
- United StatesUnited KingdomAustralia
In The Last Decade
Alan Lichtenstein
162 papers receiving 10.5k citations
Alan Lichtenstein's Hit Papers
Peers
Comparison fields: 5 of 148
- Hematology 3.4k
- Microbiology 1.1k
- Oncology 3.1k
- Genetics 1.1k
- Immunology 1.8k
Countries citing papers authored by Alan Lichtenstein
This map shows the geographic impact of Alan Lichtenstein's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alan Lichtenstein with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alan Lichtenstein more than expected).
Fields of papers citing papers by Alan Lichtenstein
This network shows the impact of papers produced by Alan Lichtenstein. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alan Lichtenstein. The network helps show where Alan Lichtenstein may publish in the future.
Co-authors
The 25 scholars most cited alongside Alan Lichtenstein, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 165 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein Hit paper breakdown → | 2003 | 1199 |
| 2 | Defensins: Antimicrobial and Cytotoxic Peptides of Mammalian Cells Hit paper breakdown → | 1993 | 881 |
| 3 | Efficacy of Pamidronate in Reducing Skeletal Events in Patients with Advanced Multiple Myeloma Hit paper breakdown → | 1996 | 848 |
| 4 | Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group. Hit paper breakdown → | 1998 | 512 |
| 5 | 1997 | 319 | |
| 6 | 2005 | 318 | |
| 7 | 2004 | 283 | |
| 8 | 1995 | 251 | |
| 9 | 1998 | 218 | |
| 10 | Enhanced sensitivity of multiple myeloma cells containing PTEN mutations to CCI-779. | 2002 | 205 |
| 11 | BCL-X expression in multiple myeloma: possible indicator of chemoresistance. | 1998 | 203 |
| 12 | The phosphatidylinositol 3-kinase/AKT kinase pathway in multiple myeloma plasma cells: roles in cytokine-dependent survival and proliferative responses. | 2000 | 196 |
| 13 | 2001 | 165 | |
| 14 | 2004 | 159 | |
| 15 | Intraperitoneal recombinant alpha-interferon for "salvage" immunotherapy in stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study. | 1985 | 153 |
| 16 | 1990 | 145 | |
| 17 | 1989 | 139 | |
| 18 | 2005 | 136 | |
| 19 | 1980 | 134 | |
| 20 | 2009 | 126 |
About Alan Lichtenstein
Alan Lichtenstein is a scholar working on Molecular Biology, Hematology, Oncology, Immunology and Pathology and Forensic Medicine, having authored 165 papers that have together received 11.0k indexed citations. Recurring topics across this work include Multiple Myeloma Research and Treatments (58 papers), PI3K/AKT/mTOR signaling in cancer (31 papers), Immune Cell Function and Interaction (20 papers), Monoclonal and Polyclonal Antibodies Research (14 papers), Cytokine Signaling Pathways and Interactions (11 papers), Protein Kinase Regulation and GTPase Signaling (10 papers), Immunotherapy and Immune Responses (10 papers) and Immune Response and Inflammation (10 papers). The work is most often cited by research in Hematology (3.4k citations), Microbiology (1.1k citations), Oncology (3.1k citations), Genetics (1.1k citations) and Immunology (1.8k citations). Alan Lichtenstein has collaborated with scholars based in United States, United Kingdom and Australia. Frequent co-authors include Tomas Ganz, Joseph Gera, Yijiang Shi, Robert I. Lehrer, Yiping Tu, Elizabeta Nemeth, Gary J. Schiller, Mary Territo, Patrick Frost and Erika V. Valore. Their work appears in journals such as Blood, Cellular Immunology, Journal of Biological Chemistry, Molecular Cancer Therapeutics and Oncogene.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.